GlassScriptPhysician profile
Randall S Williams
NPI 1245261114
$34,490.25
in general payments reported to CMS, 2019-2025
86 companies · $4,528 in 2025
The $4,528 reported for 2025 was more than what 98% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,408 · 2020: $4,053 · 2021: $5,542 · 2022: $7,371 · 2023: $4,538 · 2024: $4,050 · 2025: $4,528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,104.61 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,288.35 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $4,549.23 | 2019-2025 | Ubrelvy, Linzess, Vraylar |
| Novo Nordisk INC | $2,829.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $2,014.76 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,848.77 | 2019-2025 | Fasenra, Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,637.69 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $1,239.89 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $1,060.85 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $987.13 | 2019-2025 | Jardiance, Ofev |
| Corcept Therapeutics | $973.99 | 2019-2025 | Korlym |
| Glaxosmithkline, LLC. | $927.12 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $877.14 | 2019-2025 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Daiichi Sankyo INC. | $771.79 | 2019-2025 | Injectafer |
| Allergan, INC. | $694.97 | 2019-2020 | |
| Amarin Pharma, INC. | $688.98 | 2019-2021 |
Show all 86 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.